-
2016 biomedical industry Collaborative Innovation Summit
Time of Update: 2020-04-03
Home page: Conference background human vaccine antibody drug project docking registration, contact us Brief introduction of the meeting a bout the conference summit has a biomedical industry developme
-
The three kinds of clinical drugs, nifedipine citrate and alfatinib maleate, applied by Shiyao group were accepted
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on May 26, two kinds of three kinds of drugs applied for clinical application by Shiyao group, i.e tofetibuk citrate and alfet
-
The production site inspection of levetiracetam, an antiepileptic drug of xinlitai, has been completed
Time of Update: 2020-04-03
At the performance presentation meeting, Yang Jianfeng, Secretary of the board of directors of xinlitai, said that the drug regulatory department had come to the company this month to inspect the prod
-
Zhengda Tianqing Pharmaceutical Co., Ltd. and BioLineRx Co., Ltd. jointly develop hepatitis C treatment drug BL-8030
Time of Update: 2020-04-03
Recently, biolinerx and Jiangsu Zhengda Tianqing Pharmaceutical Co., Ltd signed a foreign license agreement According to the agreement, Zhengda Tianqing will obtain the follow-up development, producti
-
Hengrui medicine, a new diabetes drug, is expected to be put into production by the end of the year
Time of Update: 2020-04-03
Sun piaoyang, chairman of Hengrui pharmaceutical, said at a meeting organized by securities companies that the company's new diabetes drug regletin is expected to declare production by the end of this
-
Yiteng medicine is authorized to sell the new GlaxoSmithKline breast cancer drug taliza
Time of Update: 2020-04-03
Yiteng Pharmaceutical Co., Ltd., a professional pharmaceutical company, announced on April 9 that it has obtained the exclusive right to distribute thalassar, a new GlaxoSmithKline drug for the treatm
-
Zhejiang Zhenyuan ademetionine succinate is expected to obtain production approval in the first half of the year
Time of Update: 2020-04-03
Zhou Qianli, a secretary of the board of directors of Zhenyuan, Zhejiang Province, said at the strategic meeting of securities companies that the company's new drug for liver and gall, ademetionine su
-
Acceptance list of important new drugs of CDE on April 1-2
Time of Update: 2020-04-03
The following figure shows the acceptance information of important new drugs on April 1-2 organized by the big smart pharmaceutical group according to the public information of the State Food and drug
-
Clinical research stage of the new Chinese medicine "guangjinqiancao total flavonoids" capsule
Time of Update: 2020-04-03
The Research Institute of humanwell Pharmaceutical Group, the world's first new Chinese medicine drug, "total flavonoids capsule of Lysimachia grandiflora" has entered the stage of clinical research A
-
Approval for clinical trial of olanzapine fluoxetine capsule
Time of Update: 2020-04-03
Zhejiang Jinhua Kangenbei biopharmaceutical Co., Ltd., a holding subsidiary of Zhejiang Kangenbei Pharmaceutical Co., Ltd., received the approval document for clinical trial of olanzapine fluoxetine c
-
Lafutidine, a new gastric ulcer drug of Changjiang Pharmaceutical Co., Ltd
Time of Update: 2020-04-03
According to the information on the website of the State Food and Drug Administration (CFDA) on August 6, the raw materials and tablets of lafutidine, a class 3.1 chemical drug of Yichang Changjiang P
-
Double egret pharmaceutical heavy product Fu Ji complex gel is expected to be approved for production in about a month.
Time of Update: 2020-04-03
In July 2nd, the website of the State Food and Drug Administration (CFDA) showed that the state of "Fu Ji complex gel" (the full name: recombinant human basic fibroblast growth factor gel) was changed
-
The application for production of ivabradine hydrochloride tablets, a class 3.1 chemical drug of eurypharma, has been accepted
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on April 17, ivabradine hydrochloride, a class 3.1 chemical drug, which was declared to be produced by the European pharmaceut
-
Platelet aggregation inhibitors are in the Ascendant: tegrilol will become a "heavy bomb" in 2017. How about domestic declaration?
Time of Update: 2020-04-03
Although the popularity of "super heavy bomb" Plavix has been greatly reduced, it still ranks first in sales of this category with the achievement of US $1.96 billion in 2015; the follow-up excellent
-
Some new drug approval policies are expected to be issued within this year to speed up the review
Time of Update: 2020-04-03
In response to the industry's long-standing appeal that the speed of new drug review and approval is too slow, insiders involved in the formulation of new drug approval policies of the drug administra
-
Yaomingkant and AstraZeneca seize the market of rheumatoid arthritis in China
Time of Update: 2020-04-03
With the saturation of European and American pharmaceutical market, more and more biomedical giants begin to focus on the emerging market represented by China Novartis, Pfizer and other biomedical gia
-
Tonghua Dongbao's first three generations of insulin glargine obtained clinical approval within months
Time of Update: 2020-04-03
According to the information on June 3 on the website of the State Food and Drug Administration (CFDA), the third-generation insulin glargine bulk drug and preparation insulin glargine injection that
-
Irbesartan tablets approved by FDA
Time of Update: 2020-04-03
Haizheng Pharmaceutical (600267) announced in the evening of Friday (June 24) that the new drug of irbesartan tablets of Haizheng Pharmaceutical (Hangzhou) Co., Ltd., a wholly-owned subsidiary of the
-
Changchun high tech Jinsai Pharmaceutical Co., Ltd. gained clinical approval for new indication of long-term growth hormone
Time of Update: 2020-04-03
According to the website of the State Food and drug administration, the latest status of pegylated recombinant human growth hormone injection (referred to as long-acting growth hormone) applied for cl
-
Raw materials and tablets approved
Time of Update: 2020-04-03
Approval for clinical trial of drugs: approval for clinical trial of drugs obtained from raw materials and tablets of rivaroxaban, a subsidiary Recently, Zhejiang Jinhua kangenbe biopharmaceutical Co.
